Biohaven

Biohaven Operating Expenses

The Total Operating Expenses of Biohaven (BHVN) as of Oct 22, 2026 is 741.24 M USD. In the previous year, Total Operating Expenses was 885.11 M USD — a change of -16.25% (lower).

Operating Expenses

741.24 MUSD

YoY

-16.25%

Last updated:

Total Operating Expenses of Biohaven is 2025 741.24 M USD. Total Operating Expenses of Biohaven was 2024 885.11 M USD. It decreases by -16.25% lower compared to the previous year.

The Biohaven Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
224.55 M USD
Jan 1, 2019
479.12 M USD
Jan 1, 2020
114.51 M USD
Jan 1, 2021
218.90 M USD
Jan 1, 2022
567.93 M USD
Jan 1, 2023
436.05 M USD
Jan 1, 2024
885.11 M USD
Jan 1, 2025
741.24 M USD
The Biohaven Operating Expenses history
YEAROperating ExpensesYoY
741.24 MUSD-16.25%
885.11 MUSD+102.98%
436.05 MUSD-23.22%
567.93 MUSD+159.45%
218.90 MUSD+91.17%
114.51 MUSD-76.10%
479.12 MUSD+113.37%
224.55 MUSD+270.36%
60.63 MUSD+525.05%
9.70 MUSD+555.41%
1.48 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biohaven Stock analysis

What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biohaven stock

Total Operating Expenses of Biohaven is 741.24 M USD in 2025.

Total Operating Expenses of Biohaven changed from 885.11 M USD to 741.24 M USD, representing a -16.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Biohaven since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Biohaven historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Biohaven

All Key Metrics — Biohaven